Claims
- 1. A method for the treatment of bone disease in a patient suffering from such disorder comprising administering to said patient an effective amount of a composition having the formula:
- 2. A method for the treatment of inflammation in a patient suffering from such disorder comprising administering to said patient an effective amount of a composition having the formula:
- 3. A method of inhibiting cell proliferation, differentiation, or mediator release in a patient suffering from a disorder characterized by such proliferation and/or differentiation and/or mediator release comprising administering to a patient a composition selected from:
4-(naphthalen-2-ylethynyl)-6,7-dimethoxyquinazoline, 4-(4-hydroxyphenyl)-6,7-dimethoxyquinazoline hydrochloride 4-phenylacetylenyl-6,7-dimethoxyquinazoline, 4-(2-phenylphenyl)-6,7-dimethoxyquinazoline, 4-(1-methylindol-3-yl)-6,7-dimethoxyquinazoline hydrochloride, 4-(4-phenylpiperidin-1-yl)-6,7-dimethoxyquinazoline, 4-[4-(3-chlorophenyl)piperazin-1-yl]-6,7-dimethoxyquinazoline, (±)-4-(2-methyl-1,2,3,4-tetrahydroquinolin-1-yl)-6,7-dimethoxyquinazoline hydrochloride, 4-(1,2,3,4-tetrahydroquinolin-1-yl)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-methyl-4-methoxyanilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-methyl-4-chloro-anilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(2,3-dihydroindol-1-yl)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-methyl-3-trifluoromethylanilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-methyl-3-chloroanilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-methyl-3-chloroanilino)quinazoline hydrochloride and 4-(naphthalen-1-ylethynyl)-6,7-dimethoxyquinazoline; or a pharmaceutically acceptable salt thereof.
- 4. The method of claim 3 where said composition administered is selected from:
4-(indazol-5-ylamino)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-methylanilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-benzylanilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-methylanilino)-6-chloroquinazoline, 4-(N-ethyl-3-chloroanilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-methyl-4-methylanilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-benzylamino)-6,7-dimethoxyquinazoline, 4-(4-methoxybenzylamino)-6,7-dimethoxyquinazoline, 4-(3,5-dimethoxybenzylamino)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-methylanilino)quinazolin-4-yl) hydrochloride, 4-(4-morpholin-4-ylanilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(3-methoxythiophenoxy)-6,7-dimethoxyquinazoline, 4-[N-(5-indanyl)amino]-6,7-dimethoxyquinazoline hydrochloride, 4-(3-chlorothiophenoxy)-6,7-dimethoxyquinazoline, 4-(3-aminopyrazolyl)-6,7-dimethoxyquinazoline hydrochloride, 4-(1,4-benzodioxan-6-ylamino)-6,7-dimethoxyquinazoline hydrochloride, 4-(α-naphthylamino)-6,7-dimethoxyquinazoline hydrochloride, 4-(β-naphthylamino)-6,7-dimethoxyquinazoline hydrochloride, 4-(cyclohexylanilino)-6,7-dimethoxyquinazoline, 4-(N-methylanilino)-6,7-dimethoxyquinazoline hydrochloride, and 4-(3-chlorophenoxy)-6,7-dimethoxyquinazoline; or a pharmaceutically acceptable salt thereof.
- 5. A pharmaceutical composition for effectively inhibiting CSF-1R tyrosine kinase activity by exhibiting inhibition of cell proliferation and/or differentiation and/or mediator release comprising a CSF-1R receptor inhibiting effective amount of a compound selected from:
4-(naphthalen-2-ylethynyl)-6,7-dimethoxyquinazoline, 4-(4-hydroxyphenyl)-6,7-dimethoxyquinazoline hydrochloride 4-phenylacetylenyl-6,7-dimethoxyquinazoline, 4-(2-phenylphenyl)-6,7-dimethoxyquinazoline, 4-(1-methylindol-3-yl)-6,7-dimethoxyquinazoline hydrochloride, 4-(4-phenylpiperidin-1-yl)-6,7-dimethoxyquinazoline, 4-[4-(3-chlorophenyl)piperazin-1-yl]-6,7-dimethoxyquinazoline, (±)-4-(2-methyl-1,2,3,4-tetrahydroquinolin-1-yl)-6,7-dimethoxyquinazoline hydrochloride, 4-(1,2,3,4-tetrahydroquinolin-1-yl)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-methyl-4-methoxyanilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-methyl-4-chloro-anilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(2,3-dihydroindol-1-yl)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-methyl-3-trifluoromethylanilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-methyl-3-chloroanilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-methyl-3-chloroanilino)quinazoline hydrochloride and 4-(naphthalen-1-ylethynyl)-6,7-dimethoxyquinazoline; or a pharmaceutically acceptable salt thereof.
- 6. The pharmaceutical composition of claim 5 where said composition is selected from:
4-(indazol-5-ylamino)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-methylanilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-benzylanilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-methylanilino)-6-chloroquinazoline, 4-(N-ethyl-3-chloroanilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-methyl-4-methylanilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-benzylamino)-6,7-dimethoxyquinazoline, 4-(4-methoxybenzylamino)-6,7-dimethoxyquinazoline, 4-(3, 5-dimethoxybenzylamino)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-methylanilino)quinazolin-4-yl) hydrochloride, 4-(4-morpholin-4-ylanilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(3-methoxythiophenoxy)-6,7-dimethoxyquinazoline, 4-[N-(5-indanyl)amino]-6,7-dimethoxyquinazoline hydrochloride, 4-(3-chlorothiophenoxy)-6,7-dimethoxyquinazoline, 4-(3-aminopyrazolyl)-6,7-dimethoxyquinazoline hydrochloride, 4-(1,4-benzodioxan-6-ylamino)-6,7-dimethoxyquinazoline hydrochloride, 4-(α-naphthylamino)-6,7-dimethoxyquinazoline hydrochloride, 4-(β-naphthylamino)-6,7-dimethoxyquinazoline hydrochloride, 4-(cyclohexylanilino)-6,7-dimethoxyquinazoline, 4-(N-methylanilino)-6,7-dimethoxyquinazoline hydrochloride, and 4-(3-chlorophenoxy)-6,7-dimethoxyquinazoline; or a pharmaceutically acceptable salt thereof.
- 7. A compound selected from:
4-(indazol-5-ylamino)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-methylanilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-benzylanilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-methylanilino)-6-chloroquinazoline, 4-(N-ethyl-3-chloroanilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-methyl-4-methylanilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-benzylamino)-6,7-dimethoxyquinazoline, 4-(4-methoxybenzylamino)-6,7-dimethoxyquinazoline, 4-(3,5-dimethoxybenzylamino)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-methylanilino)quinazolin-4-yl) hydrochloride, 4-(4-morpholin-4-ylanilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(3-methoxythiophenoxy)-6,7-dimethoxyquinazoline, 4-[N-(5-indanyl)amino]-6,7-dimethoxyquinazoline hydrochloride, 4-(3-chlorothiophenoxy)-6,7-dimethoxyquinazoline, 4-(3-aminopyrazolyl)-6,7-dimethoxyquinazoline hydrochloride, 4-(3,6-dioxananilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(α-naphthylamino)-6,7-dimethoxyquinazoline hydrochloride, 4-(β-naphthylamino)-6,7-dimethoxyquinazoline hydrochloride, 4-(cyclohexylanilino)-6,7-dimethoxyquinazoline, 4-(N-methylanilino)-6,7-dimethoxyquinazoline hydrochloride, and 4-(3-chlorophenoxy)-6,7-dimethoxyquinazoline; or a pharmaceutically acceptable salt thereof.
- 8. A compound selected from:
4-(naphthalen-2-ylethynyl)-6,7-dimethoxyquinazoline, 4-(4-hydroxyphenyl)-6,7-dimethoxyquinazoline hydrochloride 4-phenylacetylenyl-6,7-dimethoxyquinazoline, 4-(2-phenylphenyl)-6,7-dimethoxyquinazoline, 4-(1-methylindol-3-yl)-6,7-dimethoxyquinazoline hydrochloride, 4-(4-phenylpiperidin-1-yl)-6,7-dimethoxyquinazoline, 4-[4-(3-chlorophenyl)piperazin-1-yl]-6,7-dimethoxyquinazoline, (±)-4-(2-methyl-1,2,3,4-tetrahydroquinolin-1-yl)-6,7-dimethoxyquinazoline hydrochloride, 4-(1,2,3,4-tetrahydroquinolin-1-yl)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-methyl-4-methoxyanilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-methyl-4-chloro-anilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(2,3-dihydroindol-1-yl)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-methyl-3-trifluoromethylanilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-methyl-3-chloroanilino)-6,7-dimethoxyquinazoline hydrochloride, 4-(N-methyl-3-chloroanilino)quinazoline hydrochloride and 4-(naphthalen-1-ylethynyl)-6,7-dimethoxyquinazoline; or a pharmaceutically acceptable salt thereof.
Parent Case Info
[0001] This application is a continuation-in-part application of U.S. Ser. No. 08/299,886, filed Apr. 19, 1994, which is a continuation-in-part of Ser. No. 08/166,199, filed Dec. 10, 1993, which is a continuation-in-part of Ser. No. 07/988,515, filed Dec. 10, 1992, which is a continuation-in-part application of U.S. Ser. No. 07/698,420, filed May 10, 1991 and a continuation-in-part application of PCT International Application Serial No. PCT/US92/03736, filed May 6, 1992, which has entered the U.S. National Stage as Ser. No. 08/146,072, filed Nov. 8, 1993.
Divisions (1)
|
Number |
Date |
Country |
Parent |
08521852 |
May 1995 |
US |
Child |
10617342 |
Jul 2003 |
US |
Continuation in Parts (5)
|
Number |
Date |
Country |
Parent |
08299886 |
Sep 1994 |
US |
Child |
08521852 |
May 1995 |
US |
Parent |
08166199 |
Dec 1993 |
US |
Child |
08299886 |
Sep 1994 |
US |
Parent |
07988515 |
Dec 1992 |
US |
Child |
08166199 |
Dec 1993 |
US |
Parent |
07698420 |
May 1991 |
US |
Child |
07988515 |
Dec 1992 |
US |
Parent |
PCT/US92/03736 |
May 1992 |
US |
Child |
07988515 |
Dec 1992 |
US |